AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A stable immunoglobulin preparation, wherein the preparation comprises immunoglobulin, a stabilizer comprising proline, wherein the preparation has a pH of about 4.2 to about 5.4, and wherein the preparation does not comprise nicotinamide.

2 - 3. (Cancelled)

4. (Previously presented) The preparation of claim 1, wherein proline is L-proline.

5. (Previously presented) The preparation of claim 1, wherein said preparation has a pH of about 4.5 to about 5.2.

6. (Previously presented) The preparation of claim 5, wherein said preparation has a pH of about 4.6 to about 5.0.

7. (Previously presented) The preparation of claim 1, wherein the concentration of proline in the preparation is at least 0.2 M.

8. (Previously presented) A stable immunoglobulin preparation, wherein said preparation comprises immunoglobulin, a stabilizer comprising proline, wherein the preparation has a pH of about 4.2 to about 5.4, and wherein the concentration of proline in the preparation is from 0.2 to 0.4 M.

9. (Currently amended) The preparation of claim 1 ~~or 8~~, wherein the concentration of proline is from 0.2 to 0.4 M ~~0.25 M~~.

10. (Currently amended) The preparation of claim 1 ~~or 8~~, wherein the immunoglobulin concentration of said preparation is from 5 to 25% w/v.

11. (Previously presented) The preparation of claim 10, wherein the immunoglobulin concentration of said preparation is from 15 to 20% w/v.

12. (Previously presented) The preparation of claim 10, wherein the immunoglobulin concentration of said preparation is from 6 to 15% w/v.

13. (Previously presented) The preparation of claim 12, wherein the immunoglobulin concentration of said preparation is from 8 to 12% w/v.

14. (Cancelled)

15. (Currently amended) The preparation of claim 1 ~~or 8~~, wherein said preparation is an IgG, IgA or IgM preparation.

16. (Currently amended) A pharmaceutical composition comprising the immunoglobulin preparation of claim 1 ~~or 8~~ and pharmaceutically acceptable additives.

17. (Cancelled)

18. (Withdrawn) A method of stabilizing immunoglobulin preparations, comprising providing an aqueous immunoglobulin solution and adding proline, wherein the pH of

the solution is adjusted to a pH of about 4.2 to about 5.4, and wherein the preparation does not comprise nicotinamide.

19. (Cancelled)

20. (Withdrawn) The method of claim 18, wherein the pH is adjusted to 4.8.

21. (Withdrawn) The method of claim 18, wherein the final concentration of the proline in the preparation is from 0.2 to 0.4 M.

22. - 23. (Cancelled)

24. (Withdrawn) A method of decreasing aggregate formation and/or of decreasing colouring of immunoglobulin preparations, comprising providing an aqueous immunoglobulin solution and adding proline, wherein the pH of the solution is adjusted to a pH of about 4.2 to about 5.4.

25. (Withdrawn) The method of claim 24, wherein the pH is adjusted to 4.8.

26. (Cancelled)

27. (Withdrawn) The method of claim 24, wherein the proline concentration is adjusted to from 0.2 to 0.4 M.

28. (Currently amended) The preparation of claim 1 ~~or 8~~, wherein the concentration of proline in the preparation is from 0.2 to 0.3 M.

29. (Currently amended) The preparation of claim 15, wherein the preparation is [[an]]a polyclonal IgG preparation.

30. (Previously presented) The preparation of claim 29, wherein the concentration of IgG in the preparation is 8-12% w/v.

31. (Previously presented) The preparation of claim 30, wherein the concentration of IgG in the preparation is 10% w/v.

32. (Previously presented) The preparation of claim 29, wherein said preparation has a pH of about 4.6 to about 5.0.

33. (Previously presented) The preparation of claim 29, wherein said proline is L-proline, and the concentration of L-proline in the preparation is from 0.2 to 0.3 M.

34. (Previously presented) The preparation of claim 29, wherein the preparation is a liquid preparation and has not been subject to lyophilization.

35. (Currently Amended) The preparation of claim 1 ~~or 8~~, wherein the preparation is [[an]]a polyclonal IgG preparation, the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 6-15% w/v.

36. (Previously presented) The preparation of claim 35, wherein the preparation is a liquid preparation that has not been subject to lyophilization.

37. (Currently Amended) The preparation of claim 1 ~~or 8~~, wherein the preparation is [[an]]a polyclonal IgG preparation, the preparation has a pH of about 4.6 to about 5.0, the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.3 M, and wherein the concentration of IgG in the preparation is 8-12% w/v.

38. (Previously presented) The preparation of claim 37, wherein the preparation is a liquid preparation that has not been subject to lyophilization.

39. (Currently Amended) The immunoglobulin preparation of claim 1 ~~or 8~~, wherein the preparation is [[an]]a polyclonal IgG preparation, the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 15-20% w/v.

40. (Previously presented) The preparation of claim 38, wherein the preparation is a liquid preparation that has not been subject to lyophilization.

41. (New) A stable liquid polyclonal IgG preparation, wherein the preparation comprises polyclonal IgG and a stabilizer consisting essentially of proline, wherein the preparation has a pH of about 4.2 to about 5.4, and wherein the preparation has not been subjected to lyophilization.

42. (New) The stable liquid polyclonal IgG preparation of claim 41, wherein the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 6-15% w/v.

43. (New) The stable liquid polyclonal IgG preparation of claim 41, wherein the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.3 M, and wherein the concentration of IgG in the preparation is 8-12% w/v.

44. (New) The stable liquid polyclonal IgG preparation of claim 41, wherein the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 15-20% w/v.